Preclinical data suggest that the IRAK4 inhibitor emavusertib results in lymphoma cell death in vitro with MYD88-mutated indolent B-cell lymphomas as a single agent and as a combination partner with BTK or PI3K inhibitors in unselected populations [26]. This evidence concerns the gene BTK and lymphoma.